Published on July 29, 2010 at 4:56 AM
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The principal investigator for this study has reported that the two (2) patients who were alive in March of 2010 are still alive at 3.9 and 3.5 years post dosing. This observation supports the idea that live attenuated Listeria immunotherapies can result in long lived responses, possibly by stimulating persistent immune memory.
Source Advaxis, Inc.,